Telix Pharmaceuticals (ASX:TLX) Total Receivables: A$208 Mil (As of Dec. 2025)


ASX:TLX Telix Pharmaceuticals Ltd ASX:TLX
70 GF Score
Price A$16.58
GF Value A$42.73
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Total Receivables?

Telix Pharmaceuticals ASX:TLX +2.54% 70 Total Receivables is A$208 Mil as of Dec. 2025. GuruFocus rates ASX:TLX with a GF Score™ of 70/100 and a GF Value™ of A$42.73 (Possible Value Trap). The stock has 6 warning signs investors should review.

Telix Pharmaceuticals's Total Receivables for the quarter that ended in Dec. 2025 was A$208 Mil.

Telix Pharmaceuticals Total Receivables Related Terms

Telix Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Total Receivables Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.68 39.68 73.62 157.35 208.25

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.62 89.92 157.35 198.95 208.25
ASX:TLX
70GF Score
Telix Pharmaceuticals Ltd ASX:TLX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$208 Mil mean?
Telix Pharmaceuticals (ASX:TLX) has a Total Receivables of A$208 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Total Receivables too high?
Telix Pharmaceuticals' current Total Receivables is A$208 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Total Receivables compare to VRTX and REGN?
Telix Pharmaceuticals' Total Receivables of A$208 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Total Receivables is A$208 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$42.73, compared to a current price of A$16.58 — trading 61.2% below its estimated fair value. The current Total Receivables is A$208 Mil. Telix Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current Total Receivables is A$208 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of A$16.58 is trading 61.2% below its estimated GF Value™ of A$42.73. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ASX:TLX:

  • Total Receivables: A$208 Mil
  • GF Value™: A$42.73 vs. price of A$16.58 (61.2% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Other Exchanges TLX:USATLPPF:USAT3X:Germany
Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
70GF Score

Get the complete analysis for ASX:TLX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$16.58
Price
A$42.73
GF Value